CG Oncology closed a public offering of 9.2 million shares, raising $238 million for bladder cancer therapy development.Quiver AI SummaryCG Oncology, Inc., a clinical biopharmaceutical company specializing...
CG Oncology announces public offering of 8,000,000 shares at $28 each, expected to raise $204.4 million.Quiver AI SummaryCG Oncology, Inc. has announced the pricing of its public offering of 8 million...
CG Oncology files for a public offering of 7.3 million shares, with additional shares from existing stockholders.Quiver AI SummaryCG Oncology, Inc., a clinical biopharmaceutical company focused on bladder...
LEONARD E POST, a director at $CGON ($CGON), sold 750 shares of the company on 12-06-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 75.0% of their shares....
SUO-CTC and CG Oncology announce a fellowship to advance research in Non-Muscle Invasive Bladder Cancer. Applications due February 2025.Quiver AI SummaryThe Society of Urologic Oncology Clinical Trials...
CG Oncology reports 74.5% complete response in Phase 3 trial for high-risk bladder cancer; favorable safety profile noted.Quiver AI SummaryCG Oncology, Inc. has announced encouraging topline results from...